286 related articles for article (PubMed ID: 30763151)
1. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
Yu Z; Ramakrishnan V; Meinzer C
J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
[TBL] [Abstract][Full Text] [Related]
2. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
Waleed M; He J; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
[TBL] [Abstract][Full Text] [Related]
3. Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials.
Bassi A; Berkhof J; de Jong D; van de Ven PM
Stat Methods Med Res; 2021 Mar; 30(3):717-730. PubMed ID: 33243087
[TBL] [Abstract][Full Text] [Related]
4. Group sequential multi-arm multi-stage survival trial design with treatment selection.
Wu J; Li Y
J Biopharm Stat; 2024 Jul; 34(4):453-468. PubMed ID: 37455424
[TBL] [Abstract][Full Text] [Related]
5. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
Zhou H; Chen C; Sun L; Yuan Y
Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
[TBL] [Abstract][Full Text] [Related]
6. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
8. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
Wathen JK; Thall PF
Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
[TBL] [Abstract][Full Text] [Related]
9. Predictive probability of success using surrogate endpoints.
Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
[TBL] [Abstract][Full Text] [Related]
10. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
Lu QS; Chow SC; Tse SK
J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
[TBL] [Abstract][Full Text] [Related]
11. Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information.
Rufibach K; Jordan P; Abt M
J Biopharm Stat; 2016; 26(2):191-201. PubMed ID: 25372950
[TBL] [Abstract][Full Text] [Related]
12. Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints.
Shi H; Yin G
Biometrics; 2018 Sep; 74(3):1055-1064. PubMed ID: 29466612
[TBL] [Abstract][Full Text] [Related]
13. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
Jiang Z; Song Y; Shou Q; Xia J; Wang W
Trials; 2014 Dec; 15():500. PubMed ID: 25528466
[TBL] [Abstract][Full Text] [Related]
15. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
16. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
Trials; 2011 Mar; 12():81. PubMed ID: 21418571
[TBL] [Abstract][Full Text] [Related]
17. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
18. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
Guo B; Liu S
Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
[TBL] [Abstract][Full Text] [Related]
19. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
20. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
